{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:25:08Z","timestamp":1760189108542},"reference-count":19,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,12,10]],"date-time":"2009-12-10T00:00:00Z","timestamp":1260403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Optimal salvage chemotherapy has not been established for lymphoid malignancy, which is refractory to the conventional cyclophosphamide, doxorubicin, vincristine, and prednisone regimen. To explore an effective regimen, we conducted a phase I pilot study of combination chemotherapy with methotrexate, ifosfamide, l\u2010asparaginase and dexamethasone (MILD), which are unaffected by <jats:italic>MDR1<\/jats:italic>\u2010encoded P\u2010glycoprotein. A total of 18 patients with lethal lymphoid malignancy were enrolled over a 2\u2010yr period. The median age was 63\u2003yr. Eleven patients had T\/NK\u2010cell malignancies, six had B\u2010cell malignancies, and one was diagnosed with a blastic plasmacytoid dendritic cell neoplasm. Patients aged \u226560 and &lt;60\u2003yr were planned to receive a set of starting doses of methotrexate and ifosfamide, which should induce myelosuppression. Eleven patients completed two courses of MILD therapy. Treatment\u2010related death because of systemic mucormycosis was observed in one patient. Major treatment\u2010related adverse events were grade 3 or more hematologic toxicities, which included lymphopenia corresponding to dose\u2010limiting toxicity. The most common grade 3 non\u2010hematologic toxicity was febrile neutropenia. Of the 14 evaluated patients, three achieved a complete response, and four showed a partial response. The overall response rate was 57%. It was very interesting that all of seven responders had T\/NK\u2010cell malignancies. MILD therapy was feasible and presented acceptable toxicity in patients with refractory or lethal lymphoid malignancies. The efficacy for T\/NK\u2010cell malignancies should be further evaluated.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2009.01395.x","type":"journal-article","created":{"date-parts":[[2009,12,11]],"date-time":"2009-12-11T04:31:07Z","timestamp":1260505867000},"page":"310-315","source":"Crossref","is-referenced-by-count":9,"title":["Activity and safety of combination chemotherapy with methotrexate, ifosfamide, l\u2010asparaginase and dexamethasone (MILD) for refractory lymphoid malignancies: a pilot study"],"prefix":"10.1111","volume":"84","author":[{"given":"Yutaka","family":"Tsukune","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Isobe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuna","family":"Katsuoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Hosone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuo","family":"Oshimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,3,11]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2000.1566"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.0283"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc706"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2559.2001.01076.x"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19951201)76:11<2351::AID-CNCR2820761125>3.0.CO;2-1"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg702"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960601)77:11<2302::AID-CNCR18>3.0.CO;2-0"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052603"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e3181483e1b"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145128"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2007.s.034"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2006.1.311"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00768.x"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn542"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190801959026"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06464.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2009.01395.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2009.01395.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T00:33:03Z","timestamp":1697329983000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2009.01395.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,11]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["10.1111\/j.1600-0609.2009.01395.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2009.01395.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,11]]}}}